News and Trends 18 Aug 2017 Swedish Scientists Launch Online Pathology Atlas of All Known Cancer Genes A team of Swedish researchers has published today an interactive map for the visualization of the effects of individual cancer genes that supports personalized medicine. The new Pathology Atlas is an open access online resource containing genomic data from over 8,000 patients across 17 major cancer types. By typing in the name of any gene […] August 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Aug 2017 UK Pharma Pays Over €200M for a German Drug Against Biliary Cancer Mundipharma has acquired the rights to CAP7.1, a drug that could bring the first alternative to surgery and chemo for patients with biliary tract cancer. Cambridge-based Mundipharma has paid $250M (€212M) to the German biotech CellAct in exchange for the worldwide development, commercialization and manufacturing rights to CAP7.1. The candidate is a prodrug that, when metabolized, […] August 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Aug 2017 Cancer Research UK Teams Up with London Startup in Immuno-oncology Biotecnol, based in London, has found a partner in CRUK to bring its immune-stimulating antibody into the clinic to tackle solid tumors. There will (probably) be a new immuno-oncology drug on the block soon: Cancer Research UK has gone in on London startup Biotecnol‘s antibody in a deal to bring it to an open-label Phase […] August 11, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2017 Scottish Biotech gets €4M from Horizon 2020 for Off-the-Shelf Cell Therapy TC Biopharm has just received the largest award of its kind to develop allogeneic gamma-delta T cell therapies for various cancers. Based in Glasgow, TC Biopharm was just selected to receive €4M from Horizon 2020 for its “off-the-shelf” gamma-delta T cell program. This grant brings the company’s fundraising total to €25M, and it’s the largest any UK […] August 2, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2017 Swiss Researchers Unveil Cancer Immunotherapy Resistance Mechanism Scientists from the University of Zurich have identified an epigenetic control switch responsible for turning melanoma unresponsive to immune checkpoint inhibitors. A study published this week in Cell Reports describes a mechanism that might be responsible for the development of resistance to cancer immunotherapy. The culprit turned out to be Ezh2, a protein that controls genetic […] July 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2017 AstraZeneca Misses Endpoint in Big Checkpoint Inhibitor Combo Trial AstraZeneca has announced its Phase III trial with durvalumab and tremelimumab has failed to achieve better results than standard chemotherapy in lung cancer. AstraZeneca’s MYSTIC study was evaluating a combination of checkpoint inhibitors as a first-line treatment for metastatic non-small cell lung cancer. The therapy couldn’t improve progression-free survival when compared with the standard of care […] July 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jul 2017 Roche Abandons Spanish Cancer Epigenetics Drug Roche has decided to terminate its license agreement with Spanish biotech Oryzon Genomics after rearranging its portfolio priorities. Oryzon Genomics, a biotech based in Barcelona working on epigenetics, was notified yesterday by Roche about the discontinuation of their deal concerning the biotech’s lead candidate, ORY-1001. Roche announced the decision was not based on clinical data, […] July 21, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 20 Jul 2017 SHIVA Trial: France’s Big Shot at Precision Medicine for Cancer SHIVA01 and SHIVA02 are large-scale trials run in France to evaluate the efficacy of precision medicine that have created ripples in the oncology field. Although molecular alterations are shared among different types of cancer, drug development today is still mainly based on tumor localization. The only recent exception is MSD’s Keytruda (pembrolizumab) an antibody approved by […] July 20, 2017 - 5 minutesmins - By Timothé Cynober Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2017 Update: British Biotech Starts Phase II Trial in the Second Deadliest Cancer Update (19/07/2017): Tiziana has enrolled its first patient with refractory hepatocellular carcinoma in the Phase IIa trial with milciblib. Results are expected in the fourth quarter of 2018. Published on 24/04/2017 Tiziana Life Sciences has received approval to start Phase II in Israel with its leading compound, a CDK inhibitor targeting one of the deadliest cancers. […] July 19, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 12 Jul 2017 Genomic Testing in Oncology: From Single Genes to Whole Genomes Personalized medicine would be nothing without genomic testing tools. Here’s an overview of how the field has rapidly evolved in the past years. BRCA (BReast CAncer) is one of the most famous gene variants for breast cancer testing. But aside from being a game-changer from a scientific perspective, it also changed the laws of genomic testing. […] July 12, 2017 - 5 minutesmins - By Timothé Cynober Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2017 Novartis largely dodged deaths from its CAR-T therapy, but FDA still has safety concerns Editor’s Note: Novartis did note a death from cerebral hemorrhage in its hearing with the FDA yesterday. With the application review hearing set for tomorrow, the FDA has shared its thoughts on Novartis’ CAR-T candidate. Up front are serious safety concerns. Novartis’ CTL019, or Tisagenlecleucel, wowed the audience at ASH last fall with a stellar 82% […] July 11, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2017 Results are in from the First Human Trial of an Universal Cancer Vaccine BioNTech has published results from the first clinical trial for an mRNA-based individualized vaccine with the potential to target all cancer types. Published in Nature, the results from the first trial in humans with a personalized mRNA cancer vaccine hint that BioNTech is on a promising track towards the development of a universal cancer vaccine. All […] July 5, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email